Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid
Abstract Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases. We focused 5-aminolevulinic acid (ALA) which act as electron carriers in the mitochondrial electron transport system. The mice that received ALA...
Main Authors: | Chikako Fujii, Kazutoshi Miyashita, Masanori Mitsuishi, Masaaki Sato, Kentaro Fujii, Hiroyuki Inoue, Aika Hagiwara, Sho Endo, Asuka Uto, Masaki Ryuzaki, Motowo Nakajima, Tohru Tanaka, Masanori Tamaki, Ayako Muraki, Toshihide Kawai, Hiroshi Itoh |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-03917-0 |
Similar Items
-
The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation.
by: Mai Miura, et al.
Published: (2015-01-01) -
The effects of the heme precursor 5-aminolevulinic acid (ALA) on REV-ERBα activation
by: Kohei Yamashita, et al.
Published: (2014-01-01) -
The effect of iron ion on the specificity of photodynamic therapy with 5-aminolevulinic acid.
by: Maiko Hayashi, et al.
Published: (2015-01-01) -
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)
by: Peter R. Rehani, et al.
Published: (2019-01-01) -
5-Aminolevulinic acid regulates the immune response in LPS-stimulated RAW 264.7 macrophages
by: Yuta Sugiyama, et al.
Published: (2018-12-01)